AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-137801078/safety-new-diabetes-drug.html" title="Facts and information about Safety of new diabetes drug is questioned.">Safety of new diabetes drug is questioned.</a>

Close Set up an RSS feed that alerts you when new articles from The Boston Globe (Boston, MA) are available.

Frequently asked questions about RSS feeds

Safety of new diabetes drug is questioned.

The Boston Globe (Boston, MA)

| October 21, 2005 | This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Byline: Diedtra Henderson

Oct. 21--WASHINGTON -- An experimental diabetes drug poses "an unacceptable patient hazard" because it doubles the risk that people taking it will die or have heart attacks and strokes, according to a paper the Journal of the American Medical Association rushed into publication yesterday.

The conclusion comes from Cleveland Clinic Foundation cardiologists, the same doctors that teamed up to raise an early warning flag for Vioxx. The painkiller, however, remained on the market for years, and some epidemiologists estimated it caused thousands of deaths before the it was withdrawn last fall. This time, the cardiologists say, they took…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


ImClone Deal Threatens Survival of Bristol-Myers Squibb Co.: Newspaper article from: Knight Ridder/Tribune Business News July 3, 2002 700+ words
By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business...Jul. 3--When Bristol-Myers Squibb Co. entered into its $2...can't win. "Bristol-Myers Squibb will be taken over," said...schizophrenia drug. "Bristol-Myers Squibb is the poster child," said...


Plans for Devens drug plant on course despite Bristol-Myers Squibb CEO's ouster.: News wire article from: Boston Globe (Boston, MA) September 13, 2006 700+ words
...ouster of Bristol-Myers Squibb Co.'s chief executive...businesses. Bristol-Myers Squibb applied for its construction...To see more of The Boston Globe, or to subscribe to...Copyright (c) 2006, The Boston Globe Distributed by McClatchy...


BRISTOL-MYERS SQUIBB FILES CLAIMS AGAINST CANADIAN COMPANY FOR...: Press release article from: PR Newswire July 5, 1995 700+ words
MONTREAL, July 5 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today issued the following: Bristol-Myers Squibb and Bristol-Myers Squibb Canada Inc. today announced they have filed further claims in...


Bristol-Myers Squibb Acquires Novel Antifungal From Eisai: Press release article from: PR Newswire December 12, 1996 700+ words
...Spectrum Antifungal To Expand Bristol-Myers Squibb's Infectious Disease Franchise PRINCETON...Dec. 12 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) announced today a licensing...the terms of the agreement, Bristol-Myers Squibb obtains an exclusive license worldwide...


Bristol-Myers Squibb & Phyton Agree to Commercialize Innovative Technology For...: Press release article from: PR Newswire June 4, 1998 700+ words
...PRNewswire/ -- As part of Bristol-Myers Squibb Company's continuing quest to develop...anticancer drug TAXOL(R), Bristol-Myers Squibb (NYSE: BMY) and Phyton Inc. today...licensed this technology to Bristol-Myers Squibb exclusively in 1995. TAXOL is currently...


Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share...: Press release article from: Business Wire July 31, 2008 700+ words
...around ERBITUX[R] NEW YORK -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that...equity holders of ImClone, other than Bristol-Myers Squibb. Bristol-Myers Squibb currently owns approximately 17 percent of all...


BRISTOL-MYERS SQUIBB TAKES EQUITY POSITION IN IXSYS -- WILL FUND THREE-YEAR R&D...: Press release article from: PR Newswire June 30, 1993 700+ words
...PRNewswire/ -- Ixsys, Inc. and Bristol-Myers Squibb Pharmaceutical Group announced today...signed an agreement in which Bristol-Myers Squibb will take an equity position in Ixsys...million in funding and gives Bristol-Myers Squibb a slightly more than 9 percent equity...


Bristol-Myers Squibb & Phyton Agree to Commercialize Innovative Technology for...: Press release article from: PR Newswire June 4, 1998 700+ words
...PRNewswire/ -- As part of Bristol-Myers Squibb Company's continuing quest to develop...anticancer drug TAXOL(R), Bristol-Myers Squibb (NYSE: BMY) and Phyton Inc. today...licensed this technology to Bristol-Myers Squibb exclusively in 1995. TAXOL is currently...


Bristol-Myers Squibb Announces Agreement in Principle to Resolve Federal...: Press release article from: PR Newswire May 10, 2007 700+ words
...PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company and the Antitrust Division of...settlement agreement between Bristol-Myers Squibb, its product partner, sanofi-aventis...the agreement with the DOJ, Bristol-Myers Squibb, or a subsidiary of the company, will...


Bristol-Myers Squibb Acquires Novel Oncology Drug From Manitoba Cancer...: Press release article from: PR Newswire September 5, 1996 700+ words
...Sept. 5 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY), the Manitoba...license agreement under which Bristol-Myers Squibb will develop and market DPPE, a novel...the terms of the agreement, Bristol-Myers Squibb, the world leader in cancer chemotherapy...

For more facts and information, see all results

The AccessMyLibrary advertising network includes: